<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182465</url>
  </required_header>
  <id_info>
    <org_study_id>2017/24FEV/112</org_study_id>
    <nct_id>NCT03182465</nct_id>
  </id_info>
  <brief_title>Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia</brief_title>
  <acronym>CALIF</acronym>
  <official_title>Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia According to the MASCC Score: a Prospective, Monocentric Observational Study (CALIF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CALIF study is a monocentric observational study which aim is to analyse the value of adding
      procalcitonin (PCT, a pre-hormon increased in bacterial infection and septicaemia) in the
      management of chemo-induced febrile neutropenia occurring in patient with solid tumour.
      Febrile neutropenia will be managed according to international guidelines. PCT will be dosed
      at initial presentation. Primary objective is to determine the optimal value of PCT for the
      detection of septicaemia in low risk (according to MASCC score). The investigators plan also
      to compare two risk stratification scores: the validated MASCC score and a recently developed
      score which includes PCT and other more objective items.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimum level of ProCalcitonin</measure>
    <time_frame>at day 0</time_frame>
    <description>Bacteria detection will be determined by the optimal value of ProCalcitonin in patients with solid tumors treated by chemotherapy and at low MASCC risk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the MASCC score and the Anh &amp; al score</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Based on the chareteristics of the two scores</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Febrile Neutropenia, Drug-Induced</condition>
  <arm_group>
    <arm_group_label>the predictive value of ProCalcitonin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Value of ProCalcitonin</intervention_name>
    <description>The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.</description>
    <arm_group_label>the predictive value of ProCalcitonin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more than 18 years old

          -  Patients with solid malignant tumor treated by chemotherapy (neoadjuvant,
             concomittant, adjuvant or metastatic)

          -  Febrile neutropenia chemo-induced (fever &gt; 38°C, neutrophils &lt; 500 /microliter or
             nadir &lt; 500 /microliter)

          -  Patients non hospitalized at the event (when he presented febrile neutropenia)

          -  Informed consent signed

        Exclusion Criteria:

          -  Thyroid medullar carcinoma

          -  Patient not able to understand protocol (mental retardation, psychiatric disorders,
             .... )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-Pascal Machiels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pascal Machiels, MD, PhD</last_name>
    <phone>00322764</phone>
    <phone_ext>5457</phone_ext>
    <email>jean-pascal.machiels@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gaetan Catala, MD</last_name>
    <phone>00322764</phone>
    <phone_ext>4231</phone_ext>
    <email>gaetan.catala@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pascal Machiels, MD, PhD</last_name>
      <phone>00322764</phone>
      <phone_ext>5457</phone_ext>
      <email>jean-pascal.machiels@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Gaetan Catala, MD</last_name>
      <phone>00322764</phone>
      <phone_ext>4231</phone_ext>
      <email>gaetan.catala@uclouvain.be</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Penazola, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>There is no plan to share IPD at this moment</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

